294 completed. 294 Phase 1, 74 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 294 | Completed 294 |
| Phase 2 | 74 | Completed 74 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' AD-115A, AD-1151 - Gastric Ulcer | Phase 1 | Completed | Addpharma Inc. | 46 | 2025-03-21 | 2025-10-03 |
| Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer CB CAR-NK18.2, Cyclophosphamide, Fludarabine - Gastric Cancer, Pancreas Adenocarcinoma | Phase 1 | Completed | Zhejiang Provincial People's Hospital | 9 | 2024-07-03 | 2026-07-09 |
| A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors AMG 355, Pembrolizumab - Advanced Solid Tumors | Phase 1 | Completed | Amgen | 77 | 2024-03-07 | 2026-08-11 |
| Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma T-DXd, Nivolumab, Capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Completed | National Cancer Center Hospital East | 30 | 2023-12-20 | 2026-04-14 |
| Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects. Vonoprazan Test 20mg, Vonoprazan Reference 20mg - Gastric Ulcer | Phase 1 | Completed | Hanlim Pharm. Co., Ltd. | 30 | 2023-10-23 | 2024-10-16 |
| A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 RO7496353, Atezolizumab, Capecitabine - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Genentech, Inc. | 102 | 2023-10-02 | 2026-06-18 |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fasting Conditions in Healthy Adult Volunteers BR6002A, BR6002B, BR6002 - Gastric or Duodenal Ulcers | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 40 | 2023-07-14 | 2023-12-05 |
| A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fed Conditions in Healthy Adult Volunteers BR6002A, BR6002B, BR6002 - Gastric or Duodenal Ulcer | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 40 | 2023-07-13 | 2023-11-18 |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Study of CDX-585 in Patients With Advanced Malignancies CDX-585 - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Celldex Therapeutics | 20 | 2023-05-11 | 2025-06-15 |
| A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2" BR6001-1, BR6001-2 - Gastric or Duodenal Ulcer | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 30 | 2023-03-30 | 2024-02-01 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer VIP236 (Q3W), VIP236 (Q2W) - Neoplasms | Phase 1 | Completed | Vincerx Pharma, Inc. | 29 | 2023-01-24 | 2024-11-15 |
| Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects [14C]X842 - Gastroesophageal Reflux Disease | Phase 1 | Completed | Jiangsu Sinorda Biomedicine Co., Ltd | 6 | 2022-06-15 | 2025-08-06 |
| A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers CUE-102 - Colorectal Cancer, Gastric Cancer | Phase 1 | Completed | Cue Biopharma | 42 | 2022-06-14 | 2026-01-22 |
| Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors CEA-targeted CAR-T cells - Gastric Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 17 | 2022-06-07 | 2026-07-10 |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients Cabotamig (ARB202) - Gastrointestinal Cancer, Cholangiocarcinoma | Phase 1 | Completed | Arbele Pty Ltd | 33 | 2022-05-30 | 2026-03-19 |
| Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin Irinotecan, CAPOX - Gastric Cancer, Peritoneal Metastases | Phase 1 | Completed | Erasmus Medical Center | 20 | 2022-05-25 | 2025-04-01 |
| A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells - Colorectal Cancer, Solid Cancers | Phase 1 | Completed | Weijia Fang, MD | 58 | 2022-05-25 | 2026-07-15 |
Showing 20 of 294. Sign in to see all of them.
Stomach Neoplasms (246) · Breast Neoplasms (78) · Pancreatic Neoplasms (78) · Esophageal Neoplasms (73) · Colorectal Neoplasms (64) · Carcinoma, Non-Small-Cell Lung (56) · Ovarian Neoplasms (51) · Carcinoma, Hepatocellular (44) · Colonic Neoplasms (44) · Neoplasms (44) · Melanoma (40) · Urinary Bladder Neoplasms (38) · Head and Neck Neoplasms (35) · Carcinoma, Renal Cell (34) · Gallbladder Neoplasms (33)
Digestive System Diseases (294) · Gastrointestinal Diseases (293) · Neoplasms by Site (248) · Digestive System Neoplasms (247) · Gastrointestinal Neoplasms (237) · Neoplasms (207) · Intestinal Diseases (121) · Endocrine System Diseases (116) · Endocrine Gland Neoplasms (113) · Neoplasms by Histologic Type (113) · Skin Diseases (102) · Skin and Connective Tissue Diseases (102) · Neoplasms, Glandular and Epithelial (100) · Intestinal Neoplasms (97)
Cisplatin (27) · Capecitabine (23) · Oxaliplatin (23) · Fluorouracil (19) · Irinotecan (18) · Paclitaxel (17) · Docetaxel (15) · pembrolizumab (15) · Leucovorin (14) · Nivolumab (12) · Gemcitabine (11) · Carboplatin (10) · Radiotherapy (9) · S 1 (combination) (9) · Trastuzumab (8)
National Cancer Institute (NCI) (13) · AstraZeneca (7) · GlaxoSmithKline (6) · Memorial Sloan Kettering Cancer Center (6) · Yonsei University (6) · Asan Medical Center (5) · Boryung Pharmaceutical Co., Ltd (5) · Pfizer (5) · AbbVie (4) · Amgen (4) · City of Hope Medical Center (4) · M.D. Anderson Cancer Center (4) · Novartis Pharmaceuticals (4) · Trio Medicines Ltd. (4) · Xencor, Inc. (4)
United States (170) · South Korea (56) · China (24) · Japan (24) · Spain (20) · Australia (17) · Canada (17) · Taiwan (17) · United Kingdom (16) · France (15) · Germany (12) · Netherlands (11) · Belgium (9) · Italy (8) · Poland (4)
David H. Ilson, MD, PhD (2) · Franco M. Muggia, MD (2) · Herbert K. Lyerly, MD (2) · John E. Janik, MD (2) · Malcolm Boyce (2) · Malcolm J Boyce, FRCP FFPM (2) · Naohide Yamashita, MD/PhD (2)
PMID 22607579, PMID 10628373, PMID 10811496, PMID 12196376, PMID 12393999, PMID 12454110, PMID 12663720, PMID 12680184, PMID 12885811, PMID 18470481, PMID 19192962, PMID 19706807, PMID 20068553, PMID 20179219, PMID 20407240, PMID 21448361, PMID 21994418, PMID 22464259, PMID 22631032, PMID 22738299, PMID 22961573, PMID 23207683, PMID 23228190, PMID 23228990, PMID 23333143, PMID 23394629, PMID 23613128, PMID 23639598, PMID 23665950, PMID 23756764, PMID 23930209, PMID 24013904, PMID 24091982, PMID 24987057, PMID 25687867, PMID 25900182, PMID 26811651, PMID 26908161, PMID 27709282, PMID 27911128, PMID 28119295, PMID 28196905, PMID 28378544, PMID 28782145, PMID 28899363, PMID 28973403, PMID 29505699, PMID 29954840, PMID 31068369, PMID 31138725
2016 (3), 2014 (2), 2017 (2), 2019 (2), P30CA016087 (2), P30CA016672 (2), P30CA033572 (2), P30CA068485 (2), U01CA076576 (2), 2009 (1), 2015 (1), P01DK068055 (1), P30CA013330 (1), P30CA014599 (1), P30CA015083 (1)